TY - JOUR
T1 - Exploring Nitrous Oxide as Treatment of Mood Disorders
T2 - Basic Concepts
AU - Nagele, Peter
AU - Zorumski, Charles F.
AU - Conway, Charles
N1 - Funding Information:
Dr Nagele has filed for intellectual property protection related to the use of nitrous oxide in major depression. No other conflicts of interest are related to this work. He has received research support from Roche Diagnostics, Abbot, and Express Scripts unrelated to this work. Dr Zorumski serves on the Scientific Advisory Board of Sage Therapeutics. Sage Therapeutics was not involved in this study. Dr Conway was previously on the speaker's bureau for Bristol-Myers Squibb and Otsuka Pharmaceuticals. He has received research funding from Bristol-Myers Squibb, Cyberonics, the Stanley Baer Foundation and the Brain and Behavior Research Foundation.
Funding Information:
From the *Division of Clinical and Translational Research, Department of Anesthesiology, †Taylor Family Institute for Innovative Psychiatric Research, and ‡Department of Psychiatry, Washington University in St Louis, St Louis, MO. Received September 14, 2017; accepted after revision December 12, 2017. Reprints: Peter Nagele, MD, MSc, Division of Clinical and Translational Research, Department of Anesthesiology, Washington University School of Medicine in St Louis, 660 S. Euclid Ave, Box 8054, St Louis, MO 63110 (e‐mail: [email protected]). Funding/Support: This study did not receive any extramural support and was solely funded by the Departments of Anesthesiology and Psychiatry as well as the Taylor Family Institute for Innovative Psychiatric Research at Washington University School of Medicine in St Louis. Drs Conway and Nagele are supported by a grant from the National Institute of Mental Health (5R21MH108901). Role of the funding sources: The sponsoring departments had no role in the collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0271-0749 DOI: 10.1097/JCP.0000000000000837
Publisher Copyright:
Copyright © Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Nitrous oxide (laughing gas) has shown early promise as a rapidly acting antidepressant in patients with treatment-resistant major depression and is currently investigated in several clinical trials. Because nitrous oxide is rarely administered outside operating rooms or dental practices, most psychiatrists are not familiar with how nitrous oxide is administered in a medical setting and what regulations guide its use. The goal of this brief review was to educate psychiatrists about the basic concepts of nitrous oxide administration and pharmacology. Furthermore, common misconceptions about nitrous oxide will be discussed.
AB - Nitrous oxide (laughing gas) has shown early promise as a rapidly acting antidepressant in patients with treatment-resistant major depression and is currently investigated in several clinical trials. Because nitrous oxide is rarely administered outside operating rooms or dental practices, most psychiatrists are not familiar with how nitrous oxide is administered in a medical setting and what regulations guide its use. The goal of this brief review was to educate psychiatrists about the basic concepts of nitrous oxide administration and pharmacology. Furthermore, common misconceptions about nitrous oxide will be discussed.
KW - antidepressant
KW - major depression
KW - nitrous oxide
KW - rapid onset
UR - https://www.scopus.com/pages/publications/85043487938
U2 - 10.1097/JCP.0000000000000837
DO - 10.1097/JCP.0000000000000837
M3 - Article
C2 - 29360650
AN - SCOPUS:85043487938
SN - 0271-0749
VL - 38
SP - 144
EP - 148
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
IS - 2
ER -